Patient recruitment initiated for clinical study with Lymfactin®

Patient recruitment initiated for clinical study with Lymfactin®

Pharma
Treatment
Clinical Research
News
Research
pharmaceutical

Herantis Pharma Plc (“Herantis”) has started patient recruitment for its clinical study with Lymfactin® for the treatment of breast cancer associated secondary lymphedema. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment.

“Lymfactin® is a prime example of regenerative medicine”, explains Burkhard Blank, MD, Chief Medical Officer of Herantis. “A human growth factor is harnessed for its natural purpose: To trigger the growth of new lymphatic vessels to repair the underlying cause of lymphedema. As of today an efficacious treatment of lymphedema is not known.”

“General awareness of lymphedema has increased significantly thanks to the amazing work by Hollywood actress Kathy Bates and other brave patients”, adds Pekka Simula, Herantis’ CEO. “This huge unmet clinical need is acknowledged even by the U.S. Senate. There is a will; we have strong faith that Lymfactin® can provide the way by being the first efficacious treatment to this disabling and disfiguring condition, which severely affects the quality-of-life of patients. Our clinical study will also mark the first time in the world when gene therapy is applied to repairing damage of the human lymphatic system.”

The Phase 1 clinical study is now recruiting patients with breast cancer associated lymphedema at the Helsinki University Central Hospital in Finland. Two further study sites in Finland are planned for opening later this year. The study intends to recruit at most 18 patients, and recruitment is expected to be completed in 2017.

 

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
 Herantis Pharma Plc, Katarina Jääskeläinen, Project Manager, telephone +358 50 3055 582
 Company web site: www.herantis.com
 Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

 

Read whole article at:

http://herantis.com/release/herantis-pharma-initiates-patient-recruitment-for-clinical-study-with-lymfactin-in-breast-cancer-associated-lymphedema/

 

 


Related posts